Marksans Pharma gains after receiving final nod for Loratadine Tablets from USFDA

22 Nov 2024

Marksans Pharma gains after receiving final nod for Loratadine Tablets from USFDA

The said drugs are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from hay fever and other allergies.

This product is generic version of Clartin tablet in the same strength of Bayer Healthcare.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company reported 15.8% increase in consolidated net profit to Rs 96.72 crore on 20.83% rise in revenue from operations to Rs 641.92 crore in Q2 FY25 over Q2 FY24.

Top Blogs

blog-article-image-one

Share Market

Low Price Shares

0 mins read . Dec 18, 2024

blog-article-image-one

Share Market

Nifty 50 Top 10 Stocks

0 mins read . Dec 18, 2024

blog-article-image-one

Share Market

Best Stocks in 2025

0 mins read . Dec 18, 2024

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions